Developer docs
API playgroundTry for free, no card

Search company profiles

Durbin

Full company profile

uuid000a8n5

Namestring
Durbin
Legal namestring
Durbin PLC
Company typeenum
Private
Founded yearint
1970
Descriptiontext

Durbin is a specialist medical supply company that sources and distributes pharmaceuticals, medical equipment, and consumable supplies globally. Founded in 1963 (with the Aid and Development division tracing to 1970) and headquartered in Hayes, Middlesex, near Heathrow Airport, the company operates as the UK trading entity within Uniphar Group's Product Access / On Demand division following Uniphar's 2021 acquisition. Durbin serves pharmaceutical and biotech manufacturers, healthcare professionals, NHS institutions, Ministries of Health (particularly across the Middle East), and humanitarian aid organizations across 160+ countries. The company employs 101-250 staff and supports over 20,000 medicines globally through a 550,000+ sq ft multi-temperature GDP-compliant warehouse network with cold chain (2-8°C) and frozen (-20°C) capabilities, reporting >98.5% next-day delivery success to healthcare professionals and 99.9% barcode-driven pick accuracy.

The company's offering spans eight core service lines: Clinical Trial Supply (CTS), Expanded Access Programs, Global Access (non-core market commercialization), Distribution Solutions (pre-wholesale, wholesale, bespoke, and 3PL), Unlicensed Medicines, Global Sourcing, Aid and Development, and Sexual Health Supplies. Sub-brands include Devonshire Healthcare Services (Middle East-focused hospital supply, acquired 2021) and PharmaSource (Irish market unlicensed medicines leader). The proprietary 'uniphi' cloud platform supports real-world data collection during expanded access programs with customizable dashboards, and an e-commerce portal (ps.durbinglobal.com) enables authorized HCPs to self-serve unlicensed medicine orders. Durbin holds distribution licenses from UK MHRA, HPRA (Ireland), USA Pharmacy Authorities, and the DEA, plus GDP/GMP compliance and USAID Bureau for Humanitarian Assistance approved-vendor status.

Durbin generates revenue through transaction fees on pharmaceutical distribution and wholesale, transaction fees on clinical trial supply services, managed-services contracts for 3PL and bespoke distribution, and professional-services fees for Expanded Access Program management. The go-to-motion is enterprise field sales with dedicated account managers serving key manufacturer, hospital, and aid clients, supplemented by self-serve e-commerce for unlicensed medicines. The company operates from offices in the UK (Hayes, Middlesex), Ireland (Dublin), and the United States (Ocean Springs, MS). CEO Leslie Morgan leads the company under Uniphar Group ownership (Uniphar is publicly listed on the Irish Stock Exchange).

Short descriptiontext

Durbin is a UK-headquartered specialist medical supply company, operating as the UK trading entity of Uniphar Group's Product Access division, that sources and distributes pharmaceuticals, unlicensed medicines, and medical supplies to pharma manufacturers, the NHS, Ministries of Health, and humanitarian aid organizations across 160+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical distribution, medical supply services, clinical trial supply, expanded access programs, humanitarian medical supplies
Industry2 codes
1Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
CodeHLAIAJAFPrimaryYes
2Clinical Trial Supply, Logistics & Vendor Management FSP
CodeHLAGAOAHPrimaryNo
NAICS code2 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers423450
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Pharmaceutical Distribution Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Distribution & Wholesale
TypeTransaction Fee
Description

Distribution and wholesale of licensed and unlicensed pharmaceutical products, medical devices, and healthcare supplies to hospitals, pharmacies, and healthcare professionals across global markets.

durbinglobal.com
2Clinical Trial Supply Services
TypeTransaction Fee
Description

Supply of products and ancillaries for clinical trial stages from lab-based requests through Phase 3 trials. Includes sourcing, storing, and distributing products on demand to clinical trial sites.

durbinglobal.com
3Third-Party Logistics (3PL)
TypeManaged Services
Description

Pre-wholesale, wholesale, bespoke distribution, and third-party logistics model for pharmaceutical and healthcare products. Multi-temperature controlled warehousing including ambient, cold chain (2-8°C), and frozen storage (-20°C).

durbinglobal.com
4Expanded Access Programs
TypeProfessional Services
Description

Management and facilitation of expanded access programs enabling patient access to investigational therapies, working with pharmaceutical manufacturers and healthcare providers.

durbinglobal.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Devonshire Healthcare Services
Description

Global hospital supplier specializing in pharmaceuticals and medical supplies, with extensive knowledge of the public and private sector hospitals and after-care markets, primarily serving the Middle East region.

durbinglobal.com
+3 more records
Core offering1 text field

Durbin is a specialist medical supplier that sources, distributes, and supplies licensed and unlicensed pharmaceuticals, medical devices, clinical trial supplies, and consumables to healthcare manufacturers, hospitals, pharmacies, healthcare professionals, NHS, and humanitarian aid organisations across 160+ countries. The company offers end-to-end medicine access services including clinical trial supply, expanded access programs, non-core market commercialisation, third-party logistics (3PL), global sourcing, and aid & development supply from multi-temperature controlled GDP-compliant facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • >98.5% success rate in next day HCP deliveries
+2 more records
Product overview1 text field

Durbin is a world-leading specialist medical supplier offering a portfolio of integrated products and services. The core offering consists of Clinical Trial Supply, Expanded Access Programs, Global Access (non-core market commercialisation), Distribution Solutions, Unlicensed Medicines, Global Sourcing, Aid and Development, and Sexual Health Supplies. Supporting these are sub-brands Devonshire Healthcare Services and PharmaSource. An e-commerce platform (On Demand Portal) enables healthcare professionals to access the Unlicensed Medicines Catalogue. The company is part of the Uniphar Group and holds licences from UK MHRA, HPRA, USA Pharmacy Authorities, and DEA.

Product and service11 records
1Clinical Trial Supply
CategoryClinical Trial Supply Services
Description

Global solutions providing products and ancillaries for all stages of the clinical trial and development process, from lab-based requests through Phase 3 trials, with facilities in the UK, EU, and US supporting sourcing, storage, and distribution to clinical trial sites on demand.

2Expanded Access Programs (EAP)
CategoryPatient Access Programs
Description

Management and facilitation of Expanded Access Programs (also known as Managed Access, Early Access, or Compassionate Use Programs), enabling patient access to investigational therapies through the proprietary uniphi real-world data platform while ensuring regulatory compliance.

3Global Access (Non-Core Market Commercialisation)
CategoryMarket Access Services
Description

Non-core market commercialisation services that support medicines access in markets where pharma is not yet present or wishes to exit, providing named patient sales and full-service commercialisation for pharmaceutical manufacturers.

4Distribution Solutions
CategoryThird-Party Logistics & Distribution
Description

UK distribution services from a multi-temperature controlled GDP-compliant warehouse facility in Hayes, offering pre-wholesale, wholesale, bespoke distribution, and third-party logistics (3PL) services including ambient, cold chain (2-8°C), and frozen storage (-20°C).

5Unlicensed Medicines Supply
CategorySpecialty Pharmaceutical Supply
Description

Import and supply of unlicensed pharmaceutical products for named patients and patient cohorts, addressing medicine shortages with capabilities for over 20,000 medicines globally, accessible via the ps.durbinglobal.com portal.

6Global Sourcing
CategoryInternational Pharmaceutical Sourcing
Description

International sales division within Durbin On Demand that sources and supplies pharmaceuticals and medical devices globally, including US Exports services for clinical trial supplies and named patient services.

7Aid and Development Supply
CategoryHumanitarian Medical Supply
Description

Medical supplies procurement and distribution to the developing world, serving aid organisations across 160+ countries with pharmaceuticals, consumables, medical supplies, and devices for humanitarian programmes; BHA (USAID) approved vendor.

8Sexual Health Supplies
CategorySpecialty Healthcare Supplies
Description

Supplier of sexual health products including IUDs, Manual Vacuum Aspirators, Mifepristone, condoms, lubricants, dilators, and instruments, serving NHS hospitals, CASH clinics, charities, and private healthcare providers.

9Devonshire Healthcare Services
CategoryInternational Hospital Supply
Description

Global hospital supplier specializing in pharmaceuticals and medical supplies for public and private sector hospitals, with particular expertise in the Middle East region, supplying generics, biologics, biosimilars, vaccines, and controlled drugs.

10PharmaSource
CategoryUnlicensed Medicines Supply (Ireland)
Description

Irish market leader in procurement and supply of unlicensed, difficult-to-source, and out-of-stock medicines, offering the largest portfolio of unlicensed medicines in Ireland with ecommerce platform support.

11Unlicensed Medicines On Demand Portal
CategoryPharmaceutical E-commerce Portal
Description

E-commerce platform for authorised healthcare professionals to access the Unlicensed Medicines Catalogue, manage orders, track shipments, and request certificates of analysis.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Durbin is part of the Uniphar Group, specifically within the Product Access Division. The acquisition by Uniphar in 2021 expanded Durbin's access to a wider range of medicines and products including Generics, Biologics, Biosimilars, Vaccines and Controlled Drugs. Durbin serves as the UK trading entity within Uniphar's global sourcing business.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinigen operates a near-identical service portfolio to Durbin, including unlicensed medicines supply, expanded/managed access programs, and clinical trial supply, serving pharma manufacturers and healthcare professionals globally—making it the most directly comparable peer.

TypeDirect peer
Description

Almac provides clinical trial supply, packaging, labeling, and global distribution services to pharma and biotech sponsors, overlapping directly with Durbin's CTS PTSI offering across sourcing, storage, and distribution to investigator sites.

TypeDirect peer
Description

Sharp Clinical Services (part of UDG Healthcare / Clinigen) specializes in clinical trial supply, primary and secondary packaging, and global distribution, directly competing with Durbin's clinical trial supply capabilities.

TypeBroad incumbent
Description

McKesson is one of the largest global pharmaceutical wholesalers and distributors, offering broad-line pharma distribution, specialty pharma, and clinical trial services that overlap with Durbin's distribution and CTS businesses, though at vastly larger scale.

TypeBroad incumbent
Description

Cencora is a top-tier global pharma distribution and solutions provider, including specialty distribution and clinical trial support through World Courier and other units, competing with Durbin on enterprise pharma distribution and CTS.

TypeBroad incumbent
Description

Alliance Healthcare is a major European pharmaceutical wholesaler and distributor (Walgreens Boots Alliance subsidiary) operating in the UK and across Europe, providing broad-line pharma distribution services that overlap with Durbin's distribution solutions.

TypeBroad incumbent
Description

Phoenix Group is one of Europe's largest pharmaceutical wholesale and distribution companies, operating across multiple EU territories and competing with Durbin in cross-border pharmaceutical distribution and retail pharmacy supply.

TypeBroad incumbent
Description

Cardinal Health is a major US-headquartered pharmaceutical distributor and healthcare services provider with global reach, competing with Durbin in enterprise pharma distribution and clinical/specialty pharma supply.

TypeDirect peer
Description

Movianto provides specialized pharmaceutical warehousing, distribution, and cold-chain logistics across Europe, directly comparable to Durbin's multi-temperature GDP-compliant distribution and 3PL offerings for pharma manufacturers.

TypeRegional player
Description

Zuellig Pharma is a leading pharmaceutical distribution and healthcare services provider across Asia, with comparable pharma distribution, cold chain, and specialty pharma services, though operating primarily outside Durbin's core UK/EU/US footprint.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Durbin

Pharmaceutical Distribution Servicesdurbinglobal.com

Durbin is a UK-headquartered specialist medical supply company, operating as the UK trading entity of Uniphar Group's Product Access division, that sources and distributes pharmaceuticals, unlicensed medicines, and medical supplies to pharma manufacturers, the NHS, Ministries of Health, and humanitarian aid organizations across 160+ countries.

What Durbin does

Durbin is a specialist medical supply company that sources and distributes pharmaceuticals, medical equipment, and consumable supplies globally. Founded in 1963 (with the Aid and Development division tracing to 1970) and headquartered in Hayes, Middlesex, near Heathrow Airport, the company operates as the UK trading entity within Uniphar Group's Product Access / On Demand division following Uniphar's 2021 acquisition. Durbin serves pharmaceutical and biotech manufacturers, healthcare professionals, NHS institutions, Ministries of Health (particularly across the Middle East), and humanitarian aid organizations across 160+ countries. The company employs 101-250 staff and supports over 20,000 medicines globally through a 550,000+ sq ft multi-temperature GDP-compliant warehouse network with cold chain (2-8°C) and frozen (-20°C) capabilities, reporting >98.5% next-day delivery success to healthcare professionals and 99.9% barcode-driven pick accuracy.

The company's offering spans eight core service lines: Clinical Trial Supply (CTS), Expanded Access Programs, Global Access (non-core market commercialization), Distribution Solutions (pre-wholesale, wholesale, bespoke, and 3PL), Unlicensed Medicines, Global Sourcing, Aid and Development, and Sexual Health Supplies. Sub-brands include Devonshire Healthcare Services (Middle East-focused hospital supply, acquired 2021) and PharmaSource (Irish market unlicensed medicines leader). The proprietary 'uniphi' cloud platform supports real-world data collection during expanded access programs with customizable dashboards, and an e-commerce portal (ps.durbinglobal.com) enables authorized HCPs to self-serve unlicensed medicine orders. Durbin holds distribution licenses from UK MHRA, HPRA (Ireland), USA Pharmacy Authorities, and the DEA, plus GDP/GMP compliance and USAID Bureau for Humanitarian Assistance approved-vendor status.

Durbin generates revenue through transaction fees on pharmaceutical distribution and wholesale, transaction fees on clinical trial supply services, managed-services contracts for 3PL and bespoke distribution, and professional-services fees for Expanded Access Program management. The go-to-motion is enterprise field sales with dedicated account managers serving key manufacturer, hospital, and aid clients, supplemented by self-serve e-commerce for unlicensed medicines. The company operates from offices in the UK (Hayes, Middlesex), Ireland (Dublin), and the United States (Ocean Springs, MS). CEO Leslie Morgan leads the company under Uniphar Group ownership (Uniphar is publicly listed on the Irish Stock Exchange).

Durbin firmographics

Firmographics
Name
Durbin
Legal name
Durbin PLC
Website
https://durbinglobal.com
Company type
Private
Founded year
1970
Operating status
Operating
Headcount range
101–250 employees
Short description
Durbin is a UK-headquartered specialist medical supply company, operating as the UK trading entity of Uniphar Group's Product Access division, that sources and distributes pharmaceuticals, unlicensed medicines, and medical supplies to pharma manufacturers, the NHS, Ministries of Health, and humanitarian aid organizations across 160+ countries.
Ownership category
akta.pro rank

Durbin industry classification

Industry
Product category
Pharmaceutical Distribution Services
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (42421), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro primary industry
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)
akta.pro secondary industry
Clinical Trial Supply, Logistics & Vendor Management FSP (HLAGAOAH)

Keywords

  • Pharmaceutical distribution
  • Medical supply services
  • Clinical trial supply
  • Expanded access programs
  • Humanitarian medical supplies

Where Durbin is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Durbin business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Pharmaceutical Distribution & Wholesale: Distribution and wholesale of licensed and unlicensed pharmaceutical products, medical devices, and healthcare supplies to hospitals, pharmacies, and healthcare professionals across global markets.
  2. Clinical Trial Supply Services: Supply of products and ancillaries for clinical trial stages from lab-based requests through Phase 3 trials. Includes sourcing, storing, and distributing products on demand to clinical trial sites.
  3. Third-Party Logistics (3PL): Pre-wholesale, wholesale, bespoke distribution, and third-party logistics model for pharmaceutical and healthcare products. Multi-temperature controlled warehousing including ambient, cold chain (2-8°C), and frozen storage (-20°C).
  4. Expanded Access Programs: Management and facilitation of expanded access programs enabling patient access to investigational therapies, working with pharmaceutical manufacturers and healthcare providers.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Durbin product offering

Product offering

Core offering

Durbin is a specialist medical supplier that sources, distributes, and supplies licensed and unlicensed pharmaceuticals, medical devices, clinical trial supplies, and consumables to healthcare manufacturers, hospitals, pharmacies, healthcare professionals, NHS, and humanitarian aid organisations across 160+ countries. The company offers end-to-end medicine access services including clinical trial supply, expanded access programs, non-core market commercialisation, third-party logistics (3PL), global sourcing, and aid & development supply from multi-temperature controlled GDP-compliant facilities.

Product overview

Durbin is a world-leading specialist medical supplier offering a portfolio of integrated products and services. The core offering consists of Clinical Trial Supply, Expanded Access Programs, Global Access (non-core market commercialisation), Distribution Solutions, Unlicensed Medicines, Global Sourcing, Aid and Development, and Sexual Health Supplies. Supporting these are sub-brands Devonshire Healthcare Services and PharmaSource. An e-commerce platform (On Demand Portal) enables healthcare professionals to access the Unlicensed Medicines Catalogue. The company is part of the Uniphar Group and holds licences from UK MHRA, HPRA, USA Pharmacy Authorities, and DEA.

Differentiator

Problem solved

Functional benefit

Brands

  • Devonshire Healthcare Services: Global hospital supplier specializing in pharmaceuticals and medical supplies, with extensive knowledge of the public and private sector hospitals and after-care markets, primarily serving the Middle East region.
  • PharmaSource
  • Durbin On Demand
  • CTS PTSI

Products and services

  • Clinical Trial Supply Global solutions providing products and ancillaries for all stages of the clinical trial and development process, from lab-based requests through Phase 3 trials, with facilities in the UK, EU, and US supporting sourcing, storage, and distribution to clinical trial sites on demand.
  • Expanded Access Programs (EAP) Management and facilitation of Expanded Access Programs (also known as Managed Access, Early Access, or Compassionate Use Programs), enabling patient access to investigational therapies through the proprietary uniphi real-world data platform while ensuring regulatory compliance.
  • Global Access (Non-Core Market Commercialisation) Non-core market commercialisation services that support medicines access in markets where pharma is not yet present or wishes to exit, providing named patient sales and full-service commercialisation for pharmaceutical manufacturers.
  • Distribution Solutions UK distribution services from a multi-temperature controlled GDP-compliant warehouse facility in Hayes, offering pre-wholesale, wholesale, bespoke distribution, and third-party logistics (3PL) services including ambient, cold chain (2-8°C), and frozen storage (-20°C).
  • Unlicensed Medicines Supply Import and supply of unlicensed pharmaceutical products for named patients and patient cohorts, addressing medicine shortages with capabilities for over 20,000 medicines globally, accessible via the ps.durbinglobal.com portal.
  • Global Sourcing International sales division within Durbin On Demand that sources and supplies pharmaceuticals and medical devices globally, including US Exports services for clinical trial supplies and named patient services.
  • Aid and Development Supply Medical supplies procurement and distribution to the developing world, serving aid organisations across 160+ countries with pharmaceuticals, consumables, medical supplies, and devices for humanitarian programmes; BHA (USAID) approved vendor.
  • Sexual Health Supplies Supplier of sexual health products including IUDs, Manual Vacuum Aspirators, Mifepristone, condoms, lubricants, dilators, and instruments, serving NHS hospitals, CASH clinics, charities, and private healthcare providers.
  • Devonshire Healthcare Services Global hospital supplier specializing in pharmaceuticals and medical supplies for public and private sector hospitals, with particular expertise in the Middle East region, supplying generics, biologics, biosimilars, vaccines, and controlled drugs.
  • PharmaSource Irish market leader in procurement and supply of unlicensed, difficult-to-source, and out-of-stock medicines, offering the largest portfolio of unlicensed medicines in Ireland with ecommerce platform support.
  • Unlicensed Medicines On Demand Portal E-commerce platform for authorised healthcare professionals to access the Unlicensed Medicines Catalogue, manage orders, track shipments, and request certificates of analysis.

Quantifiable outcome

  • >98.5% success rate in next day HCP deliveries
  • +2 more outcomes

Companies that use Durbin

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Durbin technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Durbin partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Uniphar GroupcoreStrategic or Co-development PartnerDurbin is part of the Uniphar Group, specifically within the Product Access Division. The acquisition by Uniphar in 2021 expanded Durbin's access to a wider range of medicines and products including Generics, Biologics, Biosimilars, Vaccines and Controlled Drugs. Durbin serves as the UK trading entity within Uniphar's global sourcing business.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Durbin competitors and assessment

Company assessment

Direct peers

  • Clinigen Group: Clinigen operates a near-identical service portfolio to Durbin, including unlicensed medicines supply, expanded/managed access programs, and clinical trial supply, serving pharma manufacturers and healthcare professionals globally—making it the most directly comparable peer.
  • Almac Group: Almac provides clinical trial supply, packaging, labeling, and global distribution services to pharma and biotech sponsors, overlapping directly with Durbin's CTS PTSI offering across sourcing, storage, and distribution to investigator sites.
  • Sharp Clinical Services: Sharp Clinical Services (part of UDG Healthcare / Clinigen) specializes in clinical trial supply, primary and secondary packaging, and global distribution, directly competing with Durbin's clinical trial supply capabilities.
  • Movianto (Owens & Minor): Movianto provides specialized pharmaceutical warehousing, distribution, and cold-chain logistics across Europe, directly comparable to Durbin's multi-temperature GDP-compliant distribution and 3PL offerings for pharma manufacturers.

Broad incumbents

  • McKesson: McKesson is one of the largest global pharmaceutical wholesalers and distributors, offering broad-line pharma distribution, specialty pharma, and clinical trial services that overlap with Durbin's distribution and CTS businesses, though at vastly larger scale.
  • Cencora (AmerisourceBergen): Cencora is a top-tier global pharma distribution and solutions provider, including specialty distribution and clinical trial support through World Courier and other units, competing with Durbin on enterprise pharma distribution and CTS.
  • Alliance Healthcare: Alliance Healthcare is a major European pharmaceutical wholesaler and distributor (Walgreens Boots Alliance subsidiary) operating in the UK and across Europe, providing broad-line pharma distribution services that overlap with Durbin's distribution solutions.
  • Phoenix Group: Phoenix Group is one of Europe's largest pharmaceutical wholesale and distribution companies, operating across multiple EU territories and competing with Durbin in cross-border pharmaceutical distribution and retail pharmacy supply.
  • Cardinal Health: Cardinal Health is a major US-headquartered pharmaceutical distributor and healthcare services provider with global reach, competing with Durbin in enterprise pharma distribution and clinical/specialty pharma supply.

Regional players

  • Zuellig Pharma: Zuellig Pharma is a leading pharmaceutical distribution and healthcare services provider across Asia, with comparable pharma distribution, cold chain, and specialty pharma services, though operating primarily outside Durbin's core UK/EU/US footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Durbin social profiles

Digital presence

Durbin compliance and trust

Trust signal

Compliance8 records

Durbin financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Durbin leadership team

Management profile

Number of profiles

Profiles1 record

Durbin subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Durbin funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Durbin M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Durbin

What does Durbin do?

Durbin is a specialist medical supplier that sources, distributes, and supplies licensed and unlicensed pharmaceuticals, medical devices, clinical trial supplies, and consumables to healthcare manufacturers, hospitals, pharmacies, healthcare professionals, NHS, and humanitarian aid organisations across 160+ countries. The company offers end-to-end medicine access services including clinical trial supply, expanded access programs, non-core market commercialisation, third-party logistics (3PL), global sourcing, and aid & development supply from multi-temperature controlled GDP-compliant facilities.

Is Durbin a public or private company?

Durbin is a private company. It is classified as corporate owned and is currently operating.

When was Durbin founded?

Durbin was founded in 1970. It employs 101 to 250 people.

Where is Durbin based?

Durbin is headquartered in London, United Kingdom, in the Europe region.

How does Durbin make money?

Four revenue lines are on record. Pharmaceutical Distribution & Wholesale is the primary driver. The others are clinical Trial Supply Services, third-Party Logistics (3PL) and expanded Access Programs.

Who are Durbin's main competitors?

Direct peers on record are Clinigen Group, Almac Group, Sharp Clinical Services and Movianto (Owens & Minor). Broad incumbents are McKesson, Cencora (AmerisourceBergen), Alliance Healthcare, Phoenix Group and Cardinal Health. Zuellig Pharma is listed as a regional player.

Does Durbin have an API?

No public API is recorded for Durbin.

What industry is Durbin in?

Durbin's product category is Pharmaceutical Distribution Services. Its primary akta.pro industry code is HLAIAJAF, Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor), with a secondary code of HLAGAOAH, Clinical Trial Supply, Logistics & Vendor Management FSP. Its NAICS code is 42421 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSIFI GIBT DIE EMA-VALIDIERUNG SEINES ZULASSUNGSANTRAGS FÜR AKANTIOR® ZUR BEHANDLUNG VON ACANTHAMOEBA-KERATITIS UND DIE ERÖFFNUNG EINES EARLY-ACCESS-PROGRAMMS BEKANNTSIFI S.p.A. announced that the European Medicines Agency (EMA) has validated its marketing authorization application for AKANTIOR® (Polihexanid), a potential first-approved treatment for Acanthamoeba keratitis. The company simultaneously launched an early-access program across Europe in partnership with Durbin to provide patients with access to the drug while awaiting final regulatory approval from the European Commission and national agencies. SIFI projects a possible approval by the second quarter of 2023, followed by an immediate market launch.PR NewswireSIFI ANNONCE L'APPROBATION PAR L'EMA DE SA DEMANDE D'AUTORISATION DE MISE SUR LE MARCHÉ D'AKANTIOR® POUR LE TRAITEMENT DE LA KÉRATITE À ACANTHAMOEBA ET L'OUVERTURE D'UN PROGRAMME D'ACCÈS ANTICIPÉSIFI S.p.A. announced that the European Medicines Agency (EMA) has validated its marketing authorization application for Akantior®, a treatment for Acanthamoeba keratitis. The company has simultaneously launched an early access program in Europe, managed in partnership with Durbin (Uniphar), to provide the drug to patients while awaiting final regulatory approval from the European Commission and UK authorities.GlobeNewswireArvelle Announces Partnership with Durbin Across EuropeArvelle Therapeutics announced a partnership with Durbin Group to distribute cenobamate via a Managed Access Program in Europe. The program allows patients with drug-resistant focal onset seizures to access the drug before commercial availability. The company received $207.8 million in start-up financing.